New drugs will fuel this dividend

Drugmaker AbbVie has held up well during the current stock market turmoil: it’s up 9% since the start of 2022 compared to the 22% drop for the S&P 500 Index.
AbbVie’s outlook remains bright, particularly as it continues to invest heavily in the development of new… Read More

T. Rowe Price still attractive

T. ROWE PRICE GROUP INC. $123 is still a buy. The mutual fund seller’s (Nasdaq symbol TROW; Aggressive Growth and Income Portfolios, Finance sector; Shares outstanding: 227.3 million; Market cap: $28.0 billion; Price-to-sales ratio: 3.6; Dividend yield: 3.9%; TSINetwork Rating: Average; www.troweprice.com) fee income varies with the value… Read More

Two stocks set to give you spinoff gains

COVID-19 has slowed the announcement of new spinoffs That’s because the new firms could have trouble attracting investors during the current stock market volatility. That, in turn, would hurt their stock prices. However, we expect spinoff activity will pick up as the pandemic eases. Here’s… Read More

Benefit from our top picks for 2019

Once again, we highlight three #1 stocks for 2019, with one for each of our portfolios—Conservative, Aggressive and Income.
All three offer a strong combination of long-term growth at a reasonable price. That should help them rise above the current stock market uncertainty to thrive this… Read More